Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.
On the evening of Feb. 15, when the dreaded letter of termination arrived, an NCI employee was just a few weeks away from job security—the end of the probationary period.
